Primary source data for business development, investors, and strategy teams. Trials, filings, patents, and markets - linked and traceable.
About RxDataLab
RxDataLab tracks clinical programs, regulatory filings, and market activity for the biotech industry. We build tools for business development teams, investors, and strategy groups who need reliable primary source data. We also publish original analysis from the same data.
Learn more →Primary-source data on the business of biotech. Clinical trials, regulatory filings, biotech hedge fund positioning, and insider trading. Updated daily.
Pipeline changes, trial status updates, and competitive landscape mapping across 450K+ trials.
Hedge fund positioning in biotech stocks, updated daily based on schedule 13 filings.
Deal activity, partnership filings, and business development signals directly from SEC filings.
Executive and director trades filed with the SEC, linked to company pipelines.
10-Q Disclosures — select overlays to view events in context
Want to explore more companies? We cover 500+ — filings, trials, insider trades, and institutional moves, all in one view.
Signup →March 24, 2026
Baker Bros filed Schedule 13D Amendment 17 on Acadia showing a renegotiated registration rights agreement allowing block trades. We pulled 14 years of Baker's 13D filing history to see what this could mean.
March 22, 2026
Genprex, Inc. strategic review ongoing (Reqorsa Gene Therapy (quaratusugene ozeplasmid)). 14 signals this week: 1 strategic, 11 financing.
March 22, 2026
Perceptive Advisors initiated new 5.3% position in Relay Therapeutics, Inc.. 4 filings this week, 3 activist, 1 passive.
Primary-source analysis of biotech companies: clinical trials, SEC filings, and hedge fund positioning. Get notified when we publish. No fixed schedule, no filler.
Traceable data for BD, investors, and strategy teams
RxDataLab links regulatory filings to clinical programs and markets, giving you the full picture of who’s filing, what trials they’re running, and how everything connects. Clinical trial records, SEC filings, patent data, and market feeds from primary sources. Every data point traces back to the original filing.
